SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending following positive Phase 3 results for its hereditary angioedema therapy, despite facing volatility from a recent equity offering. While some investors are concerned about dilution, community sentiment remains heavily focused on the stock's significant short interest, with many anticipating a potential squeeze driven by the company's long-term commercialization prospects.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is seeing increased engagement driven by a mix of broader crypto market momentum, technical breakout patterns, and persistent community speculation regarding its long-term potential in the data economy and AI-linked IoT sectors. While some investors remain highly optimistic about upcoming infrastructure and governance developments, others caution against volatility and remain skeptical, highlighting the ongoing divide between long-term proponents and those wary of past performance.

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is trending as investors weigh its role as a digital silver alternative against recent volatility and long-term price performance. The community is actively discussing potential network upgrades, the impact of upcoming halving cycles, and comparisons to other major assets, while debating whether current price levels represent a significant accumulation opportunity.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as investors weigh the potential for a regulatory path following positive data from the SOL-1 trial against the uncertainty of a single-trial NDA submission and increased competition in the ophthalmology space. The community is actively debating the likelihood of a buyout versus a standalone commercialization strategy, with sentiments split between optimism for Axpaxlis market disruption and concern over management's communication regarding regulatory timelines.

The TROLL token on the Solana network is a meme coin inspired by internet trolling culture, designed for entertainment and community engagement with no intrinsic value. Built on Solana’s blockchain, it leverages the network’s fast transactions and low fees to appeal to meme enthusiasts. Launched on decentralized exchanges, TROLL aims to foster a fun, community-driven ecosystem through social media, influencer partnerships, and viral marketing, embodying the playful spirit of online trolling.

Troll

The Troll community is heavily promoting the token as an original meme with secured IP rights, positioning it as the next major multibillion-dollar runner alongside established classics. Investors are actively debating its potential for explosive growth while emphasizing the strength of its dedicated, "OG" community culture.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta Air Lines is trending as investors weigh strong travel demand against the dual pressures of elevated jet fuel costs and geopolitical uncertainty. The community is actively discussing the airline's premium growth strategy, the potential for industry-wide capacity adjustments, and whether the robust booking environment can effectively offset margin compression.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor (TAO) is seeing a surge in investor attention as the decentralized AI network is being positioned as a censorship-resistant alternative to centralized big tech models following recent regulatory restrictions on AI access. The community is actively discussing the long-term utility of the project's subnet infrastructure and sharing bullish perspectives on the potential for AI and blockchain integration.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is trending as investors focus on a catalyst-heavy pipeline, with three major Phase 3 clinical data readouts expected throughout the remainder of 2026. The community remains sharply divided, with bulls pointing to the company's strong cash position and potential for first-in-class market disruption, while bears express significant concerns regarding historical share dilution and a lack of open-market insider buying.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF (SCHD) is trending as investors favor its defensive stability and dividend growth amidst broader market volatility, with community members actively discussing its role as a core portfolio anchor and comparing it to high-growth tech alternatives.

Nintendo Co., Ltd. engages in the development, manufacture, and sale of home entertainment products. Its entertainment products include portable and console game machines and software, trump cards and Karuta (Japanese-style playing cards), multinational consumer electronics, home console hardware such as Nintendo Wii, Nintendo DS, Nintendo 3DS, as well as software for handheld and home console gaming machines. The company was founded by Fusajiro Yamauchi on September 23, 1889 and is headquartered in Kyoto, Japan.

Nintendo Co. Ltd - ADR

Nintendo is currently the subject of intense community debate surrounding the upcoming Switch 2, with investors weighing the impact of new international trade tariffs against the company's strong brand IP and the hardware's record-breaking preorder demand. While some are concerned about the higher retail price point and manufacturing costs, many community members remain bullish, viewing Nintendo as a resilient "cash cow" with significant long-term growth potential through its expanding cinematic and theme park ecosystem.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$NGEN  
We were supposed to hear an update on NVG-300 end of Q1. 
Is it possible they already have some interest from BP that the the update we get will be license/acquisition announcement?

John Doe

David Bonanno

Matthew McCormack

Dominic desrosiers

Benjamin G

SirGicho

Tomas bermejo

StockTwits Web

NervGen Pharma Corp

$NGENF  
We were supposed to hear an update on NVG-300 end of Q1. 
Is it possible they already have some interest from BP that the the update we get will be license/acquisition announcement?

@DND603 The company is relatively short on cash and the share price is not where it was hoped post-readout. I suspect NVG-300 is in the back seat while the company determines appropriate next steps, with the focus on 291. There will be a capital raise; our approx $200MM MC is not bad, but with an ATM arrangement and our thin volume, that means there will likely be net selling pressure in the short term, lowering share price. But you do what you have to, and we have to raise capital eventually.  
We may get news on 300 but its pace would be slower than before. 
The big news will be FDA meeting and its outcome.

sammyjo

Derek moler

Broc Segura

Erin Pille

 The company is relatively short on cash and the share price is not where it was hoped post-readout. I suspect NVG-300 is in the back seat while the company determines appropriate next steps, with the focus on 291. There will be a capital raise; our approx $200MM MC is not bad, but with an ATM arrangement and our thin volume, that means there will likely be net selling pressure in the short term, lowering share price. But you do what you have to, and we have to raise capital eventually.  
We may get news on 300 but its pace would be slower than before. 
The big news will be FDA meeting and its outcome.

@EBLSA4X @DND603 Maybe  it’ll pan  out like  that. On 300, the  (non) reveal was  buried  in  the  3 April newsletter  announcing  success  in  SCI and  stroke  but providing  no data. On next  steps, I hope NervGen waits till  the  FDA has  made  a call on Accelerated Approval before raising more  cash. If AA is granted, the  stock  price  will shoot up making  requirements for cash far less dilutive. If not before, that would  be  the  time to uplist. Approval to market 291 will  also greatly reduce the  extent of further fundraising via selling stock if not eliminate it entirely. Personally, I think the chances of AA are excellent, but even if not  granted, NervGen’s future trial route will be  certain, so too therefore the need for cash….

Tim The Enchanter

 Maybe  it’ll pan  out like  that. On 300, the  (non) reveal was  buried  in  the  3 April newsletter  announcing  success  in  SCI and  stroke  but providing  no data. On next  steps, I hope NervGen waits till  the  FDA has  made  a call on Accelerated Approval before raising more  cash. If AA is granted, the  stock  price  will shoot up making  requirements for cash far less dilutive. If not before, that would  be  the  time to uplist. Approval to market 291 will  also greatly reduce the  extent of further fundraising via selling stock if not eliminate it entirely. Personally, I think the chances of AA are excellent, but even if not  granted, NervGen’s future trial route will be  certain, so too therefore the need for cash….

Andrew Commons

@EBLSA4X @DND603 … NervGen will not be  in  a  worse position by  waiting and might be in  a much  much better one. In the meantime, stock  price  should  rise as detailed data on the chronic  cohort is released providing clarity,  ending confusion and  allowing  for  the 291 success  story  to spread.

victor xyz

 … NervGen will not be  in  a  worse position by  waiting and might be in  a much  much better one. In the meantime, stock  price  should  rise as detailed data on the chronic  cohort is released providing clarity,  ending confusion and  allowing  for  the 291 success  story  to spread.

@EBLSA4X @DND603 is Nervgens next meeting with the FDA in August?

 is Nervgens next meeting with the FDA in August?

king sketti

@EBLSA4X @DND603 agree - although it will be interesting to see the full data readout in the coming weeks. There may be enough there to spark a fire of coverage. It has been very quiet, and they are sitting on a scientific and medical first - it can only stay this way for so long.

StockTwits For Android 

 agree - although it will be interesting to see the full data readout in the coming weeks. There may be enough there to spark a fire of coverage. It has been very quiet, and they are sitting on a scientific and medical first - it can only stay this way for so long.

@Nvstr2 @DND603 AA is still a possibility. Would be fantastic. One thing I&#39;m certain of: the drug needs - and deserves - much more study in SCI. (AA of course doesn&#39;t preclude that, and in fact requires it.) Two things in our favor of AA: no other good treatment options, and strong apparent drug safety. 
I am not sure we have enough capital cushion to comfortably wait for FDA action. We are still studying trial results, and even with FT the FDA process takes several months.

Aurinia Beach

 AA is still a possibility. Would be fantastic. One thing I'm certain of: the drug needs - and deserves - much more study in SCI. (AA of course doesn't preclude that, and in fact requires it.) Two things in our favor of AA: no other good treatment options, and strong apparent drug safety. 
I am not sure we have enough capital cushion to comfortably wait for FDA action. We are still studying trial results, and even with FT the FDA process takes several months.

@Lunasicc42 @DND603 No information yet on that.

@EBLSA4X @Nvstr2 @DND603   Yes short term, the best thing that can happen to NervGen and patients is accelerated approval. What do you think the odds are and good examples of similar situations getting fast approval?

   Yes short term, the best thing that can happen to NervGen and patients is accelerated approval. What do you think the odds are and good examples of similar situations getting fast approval?

Dana Allen

@Darper Not at fingertips, but AA is very occasionally (ie, rarely) granted after a very small phase 1b/2a. There are some instances. There has to be &#39;strong&#39; biomarker and functional endpoint evidence, along with credible safety data.

 Not at fingertips, but AA is very occasionally (ie, rarely) granted after a very small phase 1b/2a. There are some instances. There has to be 'strong' biomarker and functional endpoint evidence, along with credible safety data.